Search

Your search keyword '"Straus, David J."' showing total 305 results
Start Over Author "Straus, David J." Language english
305 results on '"Straus, David J."'

1. Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP

Author

Bantilan, Kurt S., Smith, Alexandra N., Maurer, Matthew J., Teruya-Feldstein, Julie, Matasar, Matthew J., Moskowitz, Alison J., Straus, David J., Noy, Ariela, Palomba, M. Lia, Horwitz, Steven M., Hamlin, Paul A., Portlock, Carol S., Cerhan, James R., Habermann, Thomas M., Salles, Gilles A., Nowakowski, Grzegorz S., Moskowitz, Craig H., and Zelenetz, Andrew D.

Published
2024
Full Text
View/download PDF

2. Retrospective characterization of nodal marginal zone lymphoma

Author

Stuver, Robert, Drill, Esther, Qualls, David, Okwali, Michelle, Lee Batlevi, Connie, Caron, Philip C., Dogan, Ahmet, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Hamlin, Paul A., Horwitz, Steven M., Imber, Brandon S., Intlekofer, Andrew M., Johnson, William T., Khan, Niloufer, Kumar, Anita, Lahoud, Oscar B., Lue, Jennifer Kimberly, Matasar, Matthew J., Moskowitz, Alison J., Noy, Ariela, Owens, Colette N., Palomba, M. Lia, Schöder, Heiko, Vardhana, Santosha A., Yahalom, Joachim, Zelenetz, Andrew D., Salles, Gilles, and Straus, David J.

Published
2023
Full Text
View/download PDF

3. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

Author

Johnson, William T., Ganesan, Nivetha, Epstein-Peterson, Zachary D., Moskowitz, Alison J., Stuver, Robert N., Maccaro, Catherine R., Galasso, Natasha, Chang, Tiffany, Khan, Niloufer, Aypar, Umut, Lewis, Natasha E., Zelenetz, Andrew D., Palomba, M. Lia, Matasar, Matthew J., Noy, Ariela, Hamilton, Audrey M., Hamlin, Paul, Caron, Philip C., Straus, David J., Intlekofer, Andrew M., Lee Batlevi, Connie, Kumar, Anita, Owens, Colette N., Sauter, Craig S., Falchi, Lorenzo, Lue, Jennifer K., Vardhana, Santosha A., Salles, Gilles, Dogan, Ahmet, Schultz, Nikolaus D., Arcila, Maria E., and Horwitz, Steven M.

Published
2023
Full Text
View/download PDF

5. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Author

Straus, David J, Długosz-Danecka, Monika, Connors, Joseph M, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J, Bartlett, Nancy L, Walewski, Jan, Ramchandren, Radhakrishnan, Zinzani, Pier Luigi, Hutchings, Martin, Munoz, Javier, Lee, Hun Ju, Kim, Won Seog, Advani, Ranjana, Ansell, Stephen M, Younes, Anas, Gallamini, Andrea, Liu, Rachael, Little, Meredith, Fenton, Keenan, Fanale, Michelle, and Radford, John

Published
2021
Full Text
View/download PDF

8. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

Author

Straus, David J., Długosz-Danecka, Monika, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Walewski, Jan, Ramchandren, Radhakrishnan, Zinzani, Pier Luigi, Hutchings, Martin, Connors, Joseph M., Radford, John, Munoz, Javier, Kim, Won Seog, Advani, Ranjana, Ansell, Stephen M., Younes, Anas, Miao, Harry, Liu, Rachael, Fenton, Keenan, Forero-Torres, Andres, and Gallamini, Andrea

Published
2020
Full Text
View/download PDF

10. Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma

Author

Borchmann, Sven, Joffe, Erel, Moskowitz, Craig H., Zelenetz, Andrew D., Noy, Ariela, Portlock, Carol S., Gerecitano, John F., Batlevi, Connie L., Caron, Philip C., Drullinsky, Pamela, Hamilton, Audrey, Hamlin, Paul A., Jr, Horwitz, Steven M., Kumar, Anita, Matasar, Matthew J., Moskowitz, Alison J., Owens, Colette N., Palomba, M. Lia, Younes, Anas, and Straus, David J.

Published
2019
Full Text
View/download PDF

12. Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma

Author

Kumar, Anita, Casulo, Carla, Yahalom, Joachim, Schöder, Heiko, Barr, Paul M., Caron, Philip, Chiu, April, Constine, Louis S., Drullinsky, Pamela, Friedberg, Jonathan W., Gerecitano, John F., Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Jacob, Alexandra G., Matasar, Matthew J., McArthur, Gianna N., McCall, Susan J., Moskowitz, Alison J., Noy, Ariela, Palomba, Maria L., Portlock, Carol S., Straus, David J., VanderEls, Nicholas, Verwys, Stephanie L., Yang, Joanna, Younes, Anas, Zelenetz, Andrew D., Zhang, Zhigang, and Moskowitz, Craig H.

Published
2016
Full Text
View/download PDF

15. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse

Author

Kumar, Anita, Sha, Fushen, Toure, Ahmed, Dogan, Ahmet, Ni, Andy, Batlevi, Connie L., Palomba, Maria Lia M., Portlock, Carol, Straus, David J., Noy, Ariela, Horwitz, Steven M., Moskowitz, Alison, Hamlin, Paul, Moskowitz, Craig H., Matasar, Matthew J., Zelenetz, Andrew D., and Younes, Anas

Published
2019
Full Text
View/download PDF

17. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

Author

Intlekofer, Andrew M., Joffe, Erel, Batlevi, Connie L., Hilden, Patrick, He, Jie, Seshan, Venkatraman E., Zelenetz, Andrew D., Palomba, M. Lia, Moskowitz, Craig H., Portlock, Carol, Straus, David J., Noy, Ariela, Horwitz, Steven M., Gerecitano, John F., Moskowitz, Alison, Hamlin, Paul, Matasar, Matthew J, Kumar, Anita, van den Brink, Marcel R., Knapp, Kristina M., Pichardo, Janine D., Nahas, Michelle K., Trabucco, Sally E., Mughal, Tariq, Copeland, Amanda R., Papaemmanuil, Elli, Moarii, Mathai, Levine, Ross L., Dogan, Ahmet, Miller, Vincent A., and Younes, Anas

Published
2018
Full Text
View/download PDF

18. Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early Stage Classic Hodgkin Lymphoma: Interim Efficacy and Safety Results from the Single-Arm Phase 2 Study (SGN35-027 Part C)

Author

Lee, Hun Ju, Abramson, Jeremy S., Bartlett, Nancy L., Burke, John M., Lynch, Ryan C., Eva, Domingo Domenech, Hess, Brian T., Schuster, Steven R., Linhares, Yuliya, Ramchandren, Rod, Gandhi, Mitul, Mowat, Rex, Shah, Harsh, Rossi, Giuseppe, Hahn, Uwe H, Prince, Henry Miles, Ho, Linda, Guo, Wenchuan, Yasenchak, Christopher A., and Straus, David J.

Published
2022
Full Text
View/download PDF

19. Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

Author

Stuver, Robert, Drill, Esther, Qualls, David, Okwali, Michelle, Batlevi, Connie Lee, Caron, Philip C, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William T., Khan, Niloufer, Lahoud, Oscar B, Lue, Jennifer Kimberly, Matasar, Matthew J., Moskowitz, Alison J., Noy, Ariela, Palomba, M.Lia, Vardhana, Santosha, Zelenetz, Andrew D., Salles, Gilles, and Straus, David J.

Published
2022
Full Text
View/download PDF

20. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Author

Wills, Beatriz, Ganesan, Nivetha, Shah, Gunjan L., Wong, Phillip, Argyropoulos, Kimon V., Sen, Filiz, Dogan, Ahmet, Straus, David J., Noy, Ariela, Kumar, Anita, Schoder, Heiko, Michaud, Laure, Palomba, Maria Lia, Falchi, Lorenzo, Lahoud, Oscar B, Hamlin, Paul A., Yahalom, Joachim, Johnson, William T., Zelenetz, Andrew D., Intlekofer, Andrew M., Owens, Colette, Batlevi, Connie Lee, Hamilton, Audrey, Caron, Philip C, Horwitz, Steven M., Galasso, Natasha, Hancock, Helen, Davey, Theresa, Santarosa, Alayna, Perez, Leslie, Capadona, Charisse, Munayirji, Brittney, Matasar, Matthew J., Pongas, Georgios, Casper, Ellie, Salles, Gilles, Moskowitz, Craig H., Vardhana, Santosha, and Moskowitz, Alison J.

Published
2022
Full Text
View/download PDF

21. Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

Author

Batlevi, Connie Lee, Drill, Esther, Okwali, Michelle, Ptashkin, Ryan, Caron, Philip C, Epstein-Peterson, Zachary D., Falchi, Lorenzo, Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Johnson, William T., Khan, Niloufer, Kumar, Anita, Lue, Jennifer Kimberly, Matasar, Matthew J., Moskowitz, Alison J., Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Straus, David J., Vardhana, Santosha, Zelenetz, Andrew D., Arcila, Maria E., Dogan, Ahmet, Seshan, Venkatraman, Salles, Gilles, Zehir, Ahmet, and Younes, Anas

Published
2022
Full Text
View/download PDF

22. Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Author

Stuver, Robert, Michaud, Laure, Casulo, Carla, Advani, Ranjana H., Budde, Elizabeth L., Barr, Paul M., Batlevi, Connie Lee, Caron, Philip C, Constine, Louis S., Dandapani, Savita, Drullinsky, Pamela, Friedberg, Jonathan W., Grieve, Clare, Hamilton, Audrey, Hamlin, Paul A., Hoppe, Richard, Horwitz, Steven M., Khan, Niloufer, Matasar, Matthew J., Noy, Ariela, Palomba, M.Lia, Schoder, Heiko, Straus, David J., Vemuri, Shreya, Yahalom, Joachim, Yang, Joanna C., Younes, Anas, Zelenetz, Andrew D., Moskowitz, Craig H., Kumar, Anita, and Moskowitz, Alison J.

Published
2022
Full Text
View/download PDF

23. Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkinʼs Lymphoma

Author

Connors, Joseph M., Jurczak, Wojciech, Straus, David J., Ansell, Stephen M., Kim, Won S., Gallamini, Andrea, Younes, Anas, Alekseev, Sergey, Illés, Árpád, Picardi, Marco, Lech-Maranda, Ewa, Oki, Yasuhiro, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Walewski, Jan, Chen, Robert, Ramchandren, Radhakrishnan, Zinzani, Pier L., Cunningham, David, Rosta, Andras, Josephson, Neil C., Song, Eric, Sachs, Jessica, Liu, Rachael, Jolin, Hina A., Huebner, Dirk, and Radford, John

Published
2018
Full Text
View/download PDF

24. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase 2 Study of an MRD-driven Approach

Author

Roeker, Lindsey E., Feldman, Tatyana A., Soumerai, Jacob D., Falco, Victoria, Panton, Gail, Dorsey, Colleen, Zelenetz, Andrew D., Falchi, Lorenzo, Park, Jae H., Straus, David J., Velasquez, Camila Pena, Lebowitz, Sonia, Fox, Yehudit, Battiato, Kristen, Laudati, Carissa, Thompson, Meghan C., McCarthy, Elizabeth, Kdiry, Sabrina, Martignetti, Rosalba, Turpuseema, Teja, Purdom, Michelle, Paskalis, Dana, Miskin, Hari P., Sportelli, Peter, Leslie, Lori A., and Mato, Anthony R.

Subjects
Neoplasm, Residual, Piperidines, Adenine, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humans, Heterocyclic Compounds, 4 or More Rings, Leukemia, Lymphocytic, Chronic, B-Cell, Article
Abstract

Ibrutinib has transformed the management of chronic lymphocytic leukemia (CLL), though its use is limited by toxicity and resistance. In this study, we utilized an "add on" approach for patients who had been treated with ibrutinib in the front-line or relapsed/refractory settings with detectable MRD. Umbralisib and ublituximab (U2) were added on to ibrutinib, patients were treated until achieving undetectable-MRD (U-MRD), and then they entered a period of treatment-free observation (TFO).Patients were eligible if they received ibrutinib in any line of therapy for at least 6 months and had detectable MRD (flow cytometry,1 cell in 10-4 cutoff for U-MRD). U2 was added to ibrutinib, and patients were monitored serially for MRD. Once U-MRD was achieved or a total of 24 cycles were administered, patients entered a period of TFO. The primary study objective was rate of U-MRD. Secondary endpoints included safety and durability of clinical benefit after treatment discontinuation.Twenty-eight patients were enrolled of whom 27 were evaluable for efficacy. Patients received ibrutinib for a median of 21 months (range 7-67) prior to study enrollment. Fourteen patients (52%) have achieved U-MRD per protocol whereas 78% had at least one U-MRD evaluation. Seventeen patients (63%) have entered TFO after a median of 6.4 months on triplet therapy. Progression-free survival at 12 months was estimated at 95%. Grade ≥3 adverse events were hypertension 7%, diarrhea 4%, and increased ALT/AST 4%.This triplet approach utilizes the addition of U2 to ibrutinib as an MRD-driven time-limited therapy. This therapy was well tolerated and effective. TFO following this therapy appears durable in ongoing follow-up.

Published
2022

29. Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting.

Author

Zheng, Serena, Gupta, Kanika, Goyal, Piyush, Nakajima, Reiko, Michaud, Laure, Batlevi, Connie Lee, Hamlin, Paul A., Horwitz, Steven, Kumar, Anita, Matasar, Matthew J., Moskowitz, Alison J., Moskowitz, Craig H., Noy, Ariela, Palomba, M. Lia, Straus, David J., Von Keudell, Gottfried, Falchi, Lorenzo, Yahalom, Joachim, Zelenetz, Andrew D., and Younes, Anas

Subjects
HODGKIN'S disease, SULFATES, DOXORUBICIN, DACARBAZINE, TREATMENT effectiveness, POSITRON emission tomography, RESEARCH funding, BLEOMYCIN, VINBLASTINE, DECISION making in clinical medicine
Abstract

Simple Summary: This study aimed to highlight limitations in the use of interim PET (iPET) for treatment decisions and prognostication in the frontline management of Hodgkin's lymphoma. It reinforces the observation from the ECHELON-1 study that outcomes of patients with a positive interim PET who nonetheless continue treatment with ABVD are not as dismal as previously described. Furthermore, we describe the performance of PET positivity grading by a quantitative measure based on SUV ratios compared to the subjective Deauville scoring. Recent prospective clinical trial data suggest that patients with Hodgkin's lymphoma who continue treatment with ABVD, despite failing to attain a complete metabolic response on interim PET (PET2+), may fare better than previously published. We describe the outcomes of PET2+ patients who continued ABVD and compare the performance of a quantitative measure based on the lesion-to-liver SUV ratio (LLS qPET2+) to that of the subjective Deauville criteria (dvPET2+). We analyzed all patients with newly diagnosed advanced-stage Hodgkin lymphoma treated with frontline ABVD at the Memorial Sloan Kettering Cancer Center between 2008 and 2017. Eligibility was set to correspond with the RATHL inclusion criteria. Images were reviewed by two nuclear medicine physicians and discordant cases were resolved with a third expert in consensus. qPET2+ was defined as LLS ≥ 1.3. We identified 227 patients of whom 25% (57) were qPET2+, but only 14% (31) were dvPET2+. Forty-eight patients (84%) continued ABVD with a 3-year PFS of 70% for qPET2+ and 64% for dvPET2+. In conclusion, interim PET interpretation in clinical practice may be associated with a higher rate of scans deemed positive. Irrespective of the criteria for PET2 positivity, a subset of patients may continue ABVD without a dismal outcome. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Phase I/II trial of vorinostat with rituximab, cyclophosphamide, etoposide and prednisone as palliative treatment for elderly patients with relapsed or refractory diffuse large B-cell lymphoma not eligible for autologous stem cell transplantation

Author

Straus, David J., Hamlin, Paul A., Matasar, Matthew J., Lia Palomba, Maria, Drullinsky, Pamela R., Zelenetz, Andrew D., Gerecitano, John F., Noy, Ariela, Hamilton, Audrey M., Elstrom, Rebecca, Wegner, Brett, Wortman, Katy, and Cella, David

Published
2015
Full Text
View/download PDF

33. Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

Author

Straus, David J., Dlugosz-Danecka, Monika, Connors, Joseph M., Illés, Árpád, Picardi, Marco, Lech-Marańda, Ewa, Feldman, Tatyana, Smolewski, Piotr, Savage, Kerry J., Bartlett, Nancy L., Walewski, Jan, Ramchandren, Radhakrishnan, Zinzani, Pier Luigi, Hutchings, Martin, Munoz, Javier, Kim, Won Seog, Advani, Ranjana, Ansell, Stephen M., Younes, Anas, Gallamini, Andrea, Liu, Rachael, Little, Meredith, Fenton, Keenan, Fanale, Michelle A., and Radford, John A.

Published
2020
Full Text
View/download PDF

34. Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era

Author

Robin, Edith Tama, Drill, Esther, Batlevi, Connie Lee, Caron, Philip, Falchi, Lorenzo, Hamilton, Audrey, Hamlin, Paul A., Horwitz, Steven M., Intlekofer, Andrew M., Joffe, Erel, Kumar, Anita, Matasar, Matthew J, Noy, Ariela, Owens, Colette, Palomba, Maria Lia, Rodriguez-Rivera, Ildefonso, Straus, David J., Vardhana, Santosha, von Keudell, Gottfried R., Zelenetz, Andrew D, Moskowitz, Craig H., and Moskowitz, Alison J.

Published
2020
Full Text
View/download PDF

35. Brentuximab Vedotin, Nivolumab, Doxorubicin, and Dacarbazine (AN+AD) for Early-Stage Classical Hodgkin Lymphoma (SGN35-027 Part C)

Author

Abramson, Jeremy S., Straus, David J., Bartlett, Nancy L., Burke, John M., Lynch, Ryan C, Domingo Domenech, Eva, Hess, Brian, Schuster, Steven R., Linhares, Yuliya, Ramchandren, Rod, Gandhi, Mitul, Mowat, Rex, Shah, Harsh, Jurczak, Wojciech, Re, Alessandro, Hahn, Uwe, Prince, H. Miles, Guo, Wenchuan, Ho, Linda, Beck, Rose C., Yasenchak, Christopher A., and Lee, Hun Ju

Published
2023
Full Text
View/download PDF

39. Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier-type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T-cell lymphoma

Author

OʼConnor, Owen A., Hamlin, Paul A., Portlock, Carol, Moskowitz, Craig H., Noy, Ariela, Straus, David J., MacGregor-Cortelli, Barbara, Neylon, Ellen, Sarasohn, Debra, Dumetrescu, Otila, Mould, Diane R., Fleischer, Martin, Zelenetz, Andrew D., Sirotnak, Frank, and Horwitz, Steven

Published
2007

48. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated burkitt lymphoma

Author

Wang, Eunice S., Straus, David J., Teruya-Feldstein, Julie, Qin, Jing, Portlock, Carol, Moskowitz, Craig, Goy, Andre, Hedrick, Eric, Zelenetz, Andrew D., and Noy, Ariela

Subjects
Chemotherapy -- Methods, Chemotherapy -- Usage, HIV (Viruses) -- Risk factors, HIV (Viruses) -- Care and treatment, Burkitt's lymphoma -- Risk factors, Health
Published
2003

Catalog

Books, media, physical & digital resources
See catalog results